Title: Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach
Abstract: Dermatologic TherapyVolume 23, Issue 6 p. 651-661 Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach Alessandro Testori, Alessandro Testori Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorGiulio Tosti, Giulio Tosti Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorChiara Martinoli, Chiara Martinoli Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorGiuseppe Spadola, Giuseppe Spadola Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorFrancesco Cataldo, Francesco Cataldo Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorFrancesco Verrecchia, Francesco Verrecchia Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorFederica Baldini, Federica Baldini Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorMassimo Mosconi, Massimo Mosconi Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorJavier Soteldo, Javier Soteldo Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorInes Tedeschi, Ines Tedeschi Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorClaudia Passoni, Claudia Passoni Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorChiara Pari, Chiara Pari Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorAlessandra Di Pietro, Alessandra Di Pietro Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorPier Francesco Ferrucci, Pier Francesco Ferrucci Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this author Alessandro Testori, Alessandro Testori Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorGiulio Tosti, Giulio Tosti Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorChiara Martinoli, Chiara Martinoli Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorGiuseppe Spadola, Giuseppe Spadola Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorFrancesco Cataldo, Francesco Cataldo Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorFrancesco Verrecchia, Francesco Verrecchia Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorFederica Baldini, Federica Baldini Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorMassimo Mosconi, Massimo Mosconi Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorJavier Soteldo, Javier Soteldo Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorInes Tedeschi, Ines Tedeschi Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorClaudia Passoni, Claudia Passoni Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorChiara Pari, Chiara Pari Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorAlessandra Di Pietro, Alessandra Di Pietro Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this authorPier Francesco Ferrucci, Pier Francesco Ferrucci Melanoma and Muscle-Cutaneous Sarcoma Division, European Institute of Oncology, Milan, ItalySearch for more papers by this author First published: 03 November 2010 https://doi.org/10.1111/j.1529-8019.2010.01370.xCitations: 100 Alessandro Testori, MD, IEO, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy, or email: [email protected]. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat ABSTRACT Electroporation uses pulsed, high-intensity electric fields to temporarily increase cell membrane permeability by creation of pores, through which small molecules, such as chemotherapeutic agents, can diffuse inside cells before they reseal. The combination of electroporation with the administration of otherwise low-permeant cytotoxic drugs is known as electrochemotherapy (ECT). The two most commonly used drugs are bleomycin and cisplatin. ECT has already been proven to be effective in diverse tumor histotypes, including melanoma and basal and squamous cell carcinoma, Kaposi sarcoma, and breast cancer, also in those cases nonresponding to classical chemotherapies or other loco-regional treatment modalities, with a good safety profile. ECT can be proposed as loco-regional therapy for disseminated cutaneous and subcutaneous tumor lesions as alternative treatment modality to conventional therapies or as palliative care, in order to improve patients' quality of life. Citing Literature Volume23, Issue6November/December 2010Pages 651-661 RelatedInformation